Cargando…

Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma

BACKGROUND: Glypican-3 (GPC3) is a newly identified target molecule for the early diagnosis of hepatocellular carcinoma (HCC), while targeted inhibition of GPC3 signaling may help to control the proliferation and metastasis of HCC cells. The purpose of this study was to prepare the anti-GPC3 nanobod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Lijie, Teng, Qiao, Chen, Qi, Zhang, Fuchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125335/ https://www.ncbi.nlm.nih.gov/pubmed/32280214 http://dx.doi.org/10.2147/IJN.S235058

Ejemplares similares

Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma
por: Li, Youwei, et al.
Publicado: (2012)

GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
por: Li, You-Cai, et al.
Publicado: (2018)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer
por: Park, Jun Young, et al.
Publicado: (2020)

Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma
por: Meng, Min, et al.
Publicado: (2021)

Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
por: Tang, Xiaolong, et al.
Publicado: (2018)

GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma
por: Ning, Jing, et al.
Publicado: (2021)

A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma
por: Zhao, Menglong, et al.
Publicado: (2018)

Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma
por: Shin, Woo-Ri, et al.
Publicado: (2022)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Correction to: GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma
por: Ning, Jing, et al.
Publicado: (2021)

Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC
por: Wang, Yuliang, et al.
Publicado: (2011)

Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
por: Homayouni, Vida, et al.
Publicado: (2016)

The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma
por: Yi, Bin, et al.
Publicado: (2021)

Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma
por: Li, Jingwen, et al.
Publicado: (2022)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Correction to: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma
por: Yi, Bin, et al.
Publicado: (2021)

GPC3 gene expression and allelic discrimination of FZD7 gene in Egyptian patients with hepatocellular carcinoma
por: Ramadan, Amany, et al.
Publicado: (2023)

Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
por: Zheng, Youshi, et al.
Publicado: (2023)

Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients
por: Mauro, Montalbano, et al.
Publicado: (2023)

Identification and characterization of blocking nanobodies against human CD70: Identification and characterization of blocking nanobodies
por: Zhang, Xin, et al.
Publicado: (2022)

Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma
por: Shao, Liwei, et al.
Publicado: (2022)

Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells
por: Zhao, Jianfeng, et al.
Publicado: (2021)

Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles
por: Deng, Han, et al.
Publicado: (2022)

DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro
por: Huang, Yao, et al.
Publicado: (2020)

GPC3 reduces cell proliferation in renal carcinoma cell lines
por: Valsechi, Marina Curado, et al.
Publicado: (2014)

A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts
por: Natarajan, Arutselvan, et al.
Publicado: (2021)

Development and Characterization of a Nanobody against Human T-Cell Immunoglobulin and Mucin-3
por: Xia, Mingyuan, et al.
Publicado: (2022)

Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression
por: Sherif, Iman O., et al.
Publicado: (2020)

GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay
por: Cao, Guozheng, et al.
Publicado: (2022)

Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging
por: Dong, Lili, et al.
Publicado: (2018)

Generation and Characterization of a Nanobody Against SARS-CoV
por: Li, Jiang-Fan, et al.
Publicado: (2021)

GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma
por: Fan, Chunmei, et al.
Publicado: (2019)

Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy
por: Shi, Yaoping, et al.
Publicado: (2023)

Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
por: Qiao, Huarui, et al.
Publicado: (2023)

Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies
por: Enriquez, Adrian S., et al.
Publicado: (2022)

Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments
por: Li, Weiyue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k48q5ra3smtol563tvlgv9nuuj